Li Y, Zhang H, Liang Y, Wang W, Xu T, Zhang J, Xiao W, Wang T, et al.
Cardiology journal. Date of publication 2018 Jan 1;volume 25(1):106-112.
1. Cardiol J. 2018;25(1):106-112. doi: 10.5603/CJ.a2017.0132.
Effects of hyperbaric oxygen on vascular endothelial function in patients with
slow coronary flow.
Li Y, Zhang H, Liang Y, Wang W, Xu T, Zhang J, Xiao W, Wang T(1).
Author information:
(1)Department of Cardiology, The Third Hospital of Hebei Medical University.
docwt781130@163.com.
BACKGROUND: To improve therapy for slow coronary flow (SCF), the effects of
hyperbaric oxygen (HBO) therapy on vascular endothelial function in SCF patients
is the focus of this investigation.
METHODS: Ninety-eight patients who exhibited chest discomfort were
retrospectively analyzed, and di-agnosed with SCF by coronary artery angiography
at the Third Hospital of Hebei Medical University, Shijiazhuang, China from 2014
to 2016. The patients were divided into two groups according to the following
treatment: HBO group (n = 48) and the control group (n = 50). Patients in the
control group were administrated with conventional treatment, while those in the
HBO group were administrated HBO therapy for 4 weeks in addition to conventional
treatment. To evaluate the effects of HBO on vas-cular endothelial functions,
plasma levels of nitric oxide (NO), calcitonin gene-related peptide (CGRP),
endothelin-1 (ET-1), high sensitivity C-reactive protein (hsCRP) as well as
endothelial-dependent flow-mediated vasodilation (FMD) of the brachial artery
were measured in both groups before and after their respective treatments.
RESULTS: There were no significant differences in plasma levels of NO, ET-1,
CGRP, hsCRP nor in FMD measurements between the two groups before treatment (p >
0.05). Moreover, the levels of all the parameters measured showed no significant
changes before and after treatment in the control group. However, when comparing
the control group, FMD and plasma NO and CGRP levels were significantly
increased in the HBO group after treatment (p < 0.01), whereas hsCRP and ET-1
levels decreased dramatically (p < 0.001).
CONCLUSIONS: The HBO treatment in addition to conventional therapy may
significantly improve the vascular endothelial function in SCF patients.
(Cardiol J 2018; 25, 1: 106-112).
DOI: 10.5603/CJ.a2017.0132
PMID: 29512098 [Indexed for MEDLINE]
